Glutaminase inhibition as potential cancer therapeutics: current status and future applications

References

• Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–314.
   PubMed Web of Science ®Google Scholar
• Maurer PH, Klevens HB, Ellenbogen E. On respiratory impairment in cancer cells. Science. 1954;24:267–268.
   Google Scholar
• Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23(1):27–47.
   PubMed Web of Science ®Google Scholar
• Mayers JR, Vander Heiden MG. Famine versus feast: Understanding the metabolism of tumors in vivo. Trends Biochem Sci. 2015;40(3):130–140.
   PubMed Web of Science ®Google Scholar
• Gaglio D, Metallo CM, Gameiro PA, Hiller K, Danna LS, Balestrieri C, Alberghina L, Stephanopoulos G, Chiaradonna F. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol Syst Biol. 2011;7(1):523.
   PubMedGoogle Scholar
• Yuneva M, Zamboni N, Oefner P, Sachidanandam R, Lazebnik Y. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol. 2007;178(1):93–105.
   PubMed Web of Science ®Google Scholar
• Lacey JM, Wilmore DW. Is glutamine a conditionally essential amino acid? Nutr Rev. 2009;48(8):297–309.
   Google Scholar
• Hosios AM, Hecht VC, Danai LV, Johnson MO, Rathmell JC, Steinhauser ML, Manalis SR, Vander Heiden MG. Amino acids rather than glucose account for the majority of cell mass in proliferating mammalian cells. Dev Cell. 2016;36(5):540–549.
   PubMed Web of Science ®Google Scholar
• Wang Y, Bai C, Ruan Y, Liu M, Chu Q, Qiu L, Yang C, Li B. Coordinative metabolism of glutamine carbon and nitrogen in proliferating cancer cells under hypoxia. Nat Commun. 2019;10(1):201.
   PubMedGoogle Scholar
• Lane AN, Fan TWM. Regulation of mammalian nucleotide metabolism and biosynthesis. Nucleic Acids Res. 2015;43(4):2466–2485.
   PubMed Web of Science ®Google Scholar
• Fendt SM, Bell EL, Keibler MA, Olenchock BA, Mayers JR, Wasylenko TM, Vokes NI, Guarente L, Heiden MGV, Stephanopoulos G. Reductive glutamine metabolism is a function of the α-ketoglutarate to citrate ratio in cells. Nat Commun. 2013;4(1):2236.
   PubMedGoogle Scholar
• Weiner ID, Hamm LL. Molecular mechanisms of renal ammonia transport. Annu Rev Physiol. 2007;69(1):317–340.
   PubMedGoogle Scholar
• Jiang L, Shestov AA, Swain P, Yang C, Parker SJ, Wang QA, Terada LS, Adams ND, McCabe MT, Pietrak B, et al. Reductive carboxylation supports redox homeostasis during anchorage-independent growth. Nature. 2016;532(7598):255–258.
   PubMed Web of Science ®Google Scholar
• Anderson PM, Lalla RV. Glutamine for amelioration of radiation and chemotherapy associated mucositis during cancer therapy. Nutrients. 2020;12(6):1675.
   PubMed Web of Science ®Google Scholar
• Stine ZE, Dang CV. Glutamine skipping the Q into mitochondria. Trends Mol Med. 2020;26(1):6–7.
   PubMed Web of Science ®Google Scholar
• Yoo HC, Park SJ, Nam M, Kang J, Kim K, Yeo JH, Kim JK, Heo Y, Lee HS, Lee MY, et al. A variant of SLC1A5 is a mitochondrial glutamine transporter for metabolic reprogramming in cancer cells. Cell Metab. 2020;31(2):267–283.e12.
   PubMed Web of Science ®Google Scholar
• Jin L, Alesi GN, Kang S. Glutaminolysis as a target for cancer therapy. Oncogene. 2016;35(28):3619–3625.
   PubMed Web of Science ®Google Scholar
• Jewell JL, Kim YC, Russell RC, Yu F-X, Park HW, Plouffe SW, Tagliabracci VS, Guan K-L. Differential regulation of mTORC1 by leucine and glutamine. Science. 2015;347(6218):194–198.
   PubMed Web of Science ®Google Scholar
• Matés JM, Campos-Sandoval JA, Márquez J. Glutaminase isoenzymes in the metabolic therapy of cancer. Biochim Biophys Acta Rev Cancer. 2018;1870(2):158–164.
   PubMed Web of Science ®Google Scholar
• Saha SK, Riazul Islam SM, Abdullah-Al-Wadud M, Islam S, Ali F, Park KS. Multiomics analysis reveals that GLS and GLS2 differentially modulate the clinical outcomes of cancer. J Clin Med. 2019;8(3):355.
   PubMed Web of Science ®Google Scholar
• Katt WP, Lukey MJ, Cerione RA. A tale of two glutaminases: homologous enzymes with distinct roles in tumorigenesis. Future Med Chem. 2017;9(2):223–243.
   PubMed Web of Science ®Google Scholar
• Xu X, Meng Y, Li L, Xu P, Wang J, Li Z, Bian J. Overview of the development of glutaminase inhibitors: achievements and future directions. J Med Chem. 2019;62(3):1096–1115.
   PubMed Web of Science ®Google Scholar
• Hartwick EW, Curthoys NP. BPTES inhibition of hGA124-551, a truncated form of human kidney-type glutaminase. J Enzyme Inhib Med Chem. 2012;27(6):861–867.
   PubMed Web of Science ®Google Scholar
• Shukla K, Ferraris DV, Thomas AG, Stathis M, Duvall B, Delahanty G, Alt J, Rais R, Rojas C, Gao P, et al. Design, synthesis, and pharmacological evaluation of bis-2-(5- phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. J Med Chem. 2012;55(23):10551–10563.
   PubMed Web of Science ®Google Scholar
• Gómez-Fabre PM, Aledo JC, Del Castillo-Olivares A, Alonso FJ, Núñez De Castro I, Campos JA, Márquez J. Molecular cloning, sequencing and expression studies of the human breast cancer cell glutaminase. Biochem J. 2000;345 Pt 2(Pt 2):365–375. PMID:10620514
   PubMedGoogle Scholar
• Katt WP, Cerione RA. Glutaminase regulation in cancer cells: a druggable chain of events. Drug Discov Today. 2014;19(4):450–457.
   PubMed Web of Science ®Google Scholar
• Chen L, Cui H. Targeting glutamine induces apoptosis: A cancer therapy approach. Int J Mol Sci. 2015;16(9):22830–22855.
   PubMed Web of Science ®Google Scholar
• Delabarre B, Gross S, Fang C, Gao Y, Jha A, Jiang F, Song J J, Wei W, Hurov JB. Full-length human glutaminase in complex with an allosteric inhibitor. Biochemistry. 2011;50(50):10764–10770.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Eid T, Hassel B, Danbolt NC. Novel aspects of glutamine synthetase in ammonia homeostasis. Neurochem Int. 2020;140:104809.
   PubMed Web of Science ®Google Scholar
• Elgadi KM, Meguid RA, Qian M, Souba WW, Abcouwer SF. Cloning and analysis of unique human glutaminase isoforms generated by tissue-specific alternative splicing. Physiol Genomics. 1999;1(2):51–62.
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang C, Lin M, Zhu W, Liang Y, Hong X, Zhao Y, Young KH, Hu W, Feng Z. Glutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinoma. Oncotarget. 2014;5(9):2635–2647.
   PubMedGoogle Scholar
• Gross MI, Demo SD, Dennison JB, Chen L, Chernov-Rogan T, Goyal B, Janes JR, Laidig GJ, Lewis ER, Li J, et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther. 2014;13(4):890–901.
   PubMed Web of Science ®Google Scholar
• Jacque N, Ronchetti AM, Larrue C, Meunier G, Birsen R, Willems L, Saland E, Decroocq J, Maciel TT, Lambert M, et al. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition. Blood. 2015;126(11):1346–1356.
   PubMed Web of Science ®Google Scholar
• Krebs HA. 1980. Glutamine metabolism in the animal body. In: Mora J, editor. Glutamine: Metabolism, enzymology, and regulation. 1st ed. New York: Academic Press.
   Google Scholar
• Kovacevic Z, McGivan JD. Mitochondrial metabolism of glutamine and glutamate and its physiological significance. Physiol Rev. 1983;63(2):547–605.
   PubMed Web of Science ®Google Scholar
• Campos-Sandoval JA, López de la Oliva AR, Lobo C, Segura JA, Matés JM, Alonso FJ, Márquez J. Expression of functional human glutaminase in baculovirus system: Affinity purification, kinetic and molecular characterization. Int J Biochem Cell Biol. 2007;39(4):765–773.
   PubMed Web of Science ®Google Scholar
• Thangavelu K, Pan CQ, Karlberg T, Balaji G, Uttamchandani M, Suresh V, Schüler H, Low BC, Sivaraman J. Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism. Proc Natl Acad Sci U S A. 2012;109(20):7705–7710.
   PubMed Web of Science ®Google Scholar
• Daye D, Wellen KE. Metabolic reprogramming in cancer: Unraveling the role of glutamine in tumorigenesis. Semin Cell Dev Biol. 2012;23(4):362–369.
   PubMed Web of Science ®Google Scholar
• Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT, et al. C-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009;458(7239):762–765.
   PubMed Web of Science ®Google Scholar
• Yue M, Jiang J, Gao P, Liu H, Qing G. Oncogenic MYC activates a feedforward regulatory loop promoting essential amino acid metabolism and tumorigenesis. Cell Rep. 2017;21(13):3819–3832.
   PubMed Web of Science ®Google Scholar
• Wise DR, Deberardinis RJ, Mancuso A, Sayed N, Zhang X-Y, Pfeiffer HK, Nissim I, Daikhin E, Yudkoff M, Mcmahon SB, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A. 2008;105(48):18782–18787.
   PubMed Web of Science ®Google Scholar
• Rathore MG, Saumet A, Rossi JF, De Bettignies C, Tempé D, Lecellier CH, Villalba M. The NF-κB member p65 controls glutamine metabolism through miR-23a. Int J Biochem Cell Biol. 2012;44(9):1448–1456.
   PubMed Web of Science ®Google Scholar
• Lukey MJ, Greene KS, Erickson JW, Wilson KF, Cerione RA. The oncogenic transcription factor c-Jun regulates glutaminase expression and sensitizes cells to glutaminase-targeted therapy. Nat Commun. 2016;7(1):11321.
   PubMedGoogle Scholar
• Prior IA, Lewis PD, Mattos C. A comprehensive survey of ras mutations in cancer. Cancer Res. 2012;72(10):2457–2467.
   PubMed Web of Science ®Google Scholar
• Wang Z, Liu F, Fan N, Zhou C, Li D, Macvicar T, Dong Q, Bruns CJ, Zhao Y. Targeting glutaminolysis: new perspectives to understand cancer development and novel strategies for potential target therapies. Front Oncol. 2020;10:589508.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay S, Goswami D, Adiseshaiah PP, Burgan W, Yi M, Guerin TM, Kozlov SV, Nissley DV, McCormick F. Undermining glutaminolysis bolsters chemotherapy while NRF2 promotes chemoresistance in KRAS-driven pancreatic cancers. Cancer Res. 2020;80(8):1630–1643.
   PubMed Web of Science ®Google Scholar
• Galan-Cobo A, Sitthideatphaiboon P, Qu X, Poteete A, Pisegna MA, Tong P, Chen PH, Boroughs LK, Rodriguez MLM, Zhang W, et al. LKB1 and KEAP1/NRF2 pathways cooperatively promote metabolic reprogramming with enhanced glutamine dependence inKRAS-mutant lung adenocarcinoma. Cancer Res. 2019;79(13):3251–3267.
   PubMed Web of Science ®Google Scholar
• Zhu W, Radadiya A, Bisson C, Nordin BE, Baumann P, Imasaki T, Wenzel SA, Sedelnikova SE, Berry AH, Nomanbhoy TK, et al. Molecular basis of human asparagine synthetase inhibitor specificity. bioRxiv. 2018;PPR:PPR57405.
   Google Scholar
• Spencer ND, Bristow CA, Giulani V, Miller MA, Carugo A, Harris AL, Minelli R, Feng N, Chang Q, Soth MJ, et al. Abstract 87: Asparagine synthetase (ASNS) expression predicts response to the GLS1 inhibitor IPN60090 in ovarian cancer through selective modulation of redox homeostasis. Cancer Res. 2021;81(13_Supplement):87–87.
   Web of Science ®Google Scholar
• Sormendi S, Wielockx B. Hypoxia pathway proteins as central mediators of metabolism in the tumor cells and their microenvironment. Front Immunol. 2018;9:40.
   PubMed Web of Science ®Google Scholar
• Metallo CM, Gameiro PA, Bell EL, Mattaini KR, Yang J, Hiller K, Jewell CM, Johnson ZR, Irvine DJ, Guarente L, et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature. 2012;481(7381):380–384.
   Web of Science ®Google Scholar
• Xiang L, Mou J, Shao B, Wei Y, Liang H, Takano N, Semenza GL, Xie G. Glutaminase 1 expression in colorectal cancer cells is induced by hypoxia and required for tumor growth, invasion, and metastatic colonization. Cell Death Dis. 2019;10(2):40.
   PubMedGoogle Scholar
• Wilson KF, Erickson JW, Antonyak MA, Cerione RA. Rho GTPases and their roles in cancer metabolism. Trends Mol Med. 2013;19(2):74–82.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Tanaka T, Poyurovsky MV, Nagano H, Mayama T, Ohkubo S, Lokshin M, Hosokawa H, Nakayama T, Suzuki Y, et al. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci U S A. 2010;107(16):7461–7466.
   PubMed Web of Science ®Google Scholar
• Chen JQ, Russo J. Dysregulation of glucose transport, glycolysis, TCA cycle and glutaminolysis by oncogenes and tumor suppressors in cancer cells. Biochim Biophys Acta Rev Cancer. 2012;1826(2):370–384.
   PubMed Web of Science ®Google Scholar
• Arianna G, Bongiorno-Borbone L, Bernassola F, Terrinoni A, Markert E, Levine AJ, Fen Z, Agostini M, Zolla L, Finazzi Agro’ A, et al. P63 regulates glutaminase 2 expression. Cell Cycle. 2013;12(9):1395–1405.
   PubMed Web of Science ®Google Scholar
• Velletri T, Romeo F, Tucci P, Peschiaroli A, Annicchiarico-Petruzzelli M, Niklison-Chirou MV, Amelio I, Knight RA, Mak TW, Melino G, et al. GLS2 is transcriptionally regulated by p73 and contributes to neuronal differentiation. Cell Cycle. 2013;12(22):3564–3573.
   PubMed Web of Science ®Google Scholar
• Gregory MA, Nemkov T, Park HJ, Zaberezhnyy V, Gehrke S, Adane B, Jordan CT, Hansen KC, D'Alessandro A, DeGregori J. Targeting glutamine metabolism and redox state for leukemia therapy. Clin Cancer Res. 2019;25(13):4079–4090.
   PubMed Web of Science ®Google Scholar
• Le A, Lane AN, Hamaker M, Bose S, Gouw A, Barbi J, Tsukamoto T, Rojas CJ, Slusher BS, Zhang H, et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab. 2012;15(1):110–121.
   PubMed Web of Science ®Google Scholar
• Yuan L, Sheng X, Clark LH, Zhang L, Guo H, Jones HM, Willson AK, Gehrig PA, Zhou C, Bae-Jump VL. Original Article Glutaminase inhibitor compound 968 inhibits cell proliferation and sensitizes paclitaxel in ovarian cancer. Am J Transl Res. 2016;8(10):4265–4277. PMID:27830010
   PubMed Web of Science ®Google Scholar
• Masamha CP, LaFontaine P. Molecular targeting of glutaminase sensitizes ovarian cancer cells to chemotherapy. J Cell Biochem. 2018;119(7):6136–6145.
   PubMed Web of Science ®Google Scholar
• Leone RD, Zhao L, Englert JM, Sun I-M, Oh M-H, Sun I-H, Arwood ML, Bettencourt IA, Patel CH, Wen J, et al. Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. Science. 2019;366(6468):1013–1021.
   PubMed Web of Science ®Google Scholar
• Lemberg KM, Vornov JJ, Rais R, Slusher BS. We’re not “don” yet: Optimal dosing and prodrug delivery of 6-diazo-5-oxo-L-norleucine. Mol Cancer Ther. 2018;17(9):1824–1832.
   PubMed Web of Science ®Google Scholar
• Rais R, Lemberg KM, Tenora L, Arwood ML, Pal A, Alt J, Wu Y, Lam J, Marie J, Aguilar H, et al. Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug. Sci Adv. 2022;8(46):eabq5925.
   PubMed Web of Science ®Google Scholar
• Hanaford AR, Alt J, Rais R, Wang SZ, Kaur H, Thorek DLJ, Eberhart CG, Slusher BS, Martin AM, Raabe EH. Orally bioavailable glutamine antagonist prodrug JHU-083 penetrates mouse brain and suppresses the growth of MYC-driven medulloblastoma. Transl Oncol. 2019;12(10):1314–1322.
   PubMed Web of Science ®Google Scholar
• Rais R, Jančařík A, Tenora L, Nedelcovych M, Alt J, Englert J, Rojas C, Le A, Elgogary A, Tan J, et al. Discovery of 6-Diazo-5-oxo- l -norleucine (DON) prodrugs with enhanced CSF delivery in monkeys: A potential treatment for glioblastoma. J Med Chem. 2016;59(18):8621–8633.
   PubMed Web of Science ®Google Scholar
• Nedelcovych MT, Tenora L, Kim BH, Kelschenbach J, Chao W, Hadas E, Jančařík A, Prchalová E, Zimmermann SC, Dash RP, et al. N-(Pivaloyloxy)alkoxy-carbonyl prodrugs of the glutamine antagonist 6-Diazo-5-oxo- l -norleucine (DON) as a potential treatment for HIV associated neurocognitive disorders. J Med Chem. 2017;60(16):7186–7198.
   PubMed Web of Science ®Google Scholar
• Curthoys NP, Watford M. Regulation of glutaminase activity and glutamine metabolism. Annu Rev Nutr. 1995;15(1):133–159.
   PubMedGoogle Scholar
• Ramachandran S, Qiurong Pan C, Zimmermann SC, Duvall B, Tsukamoto T, Low BC, Sivaraman J. Structural basis for exploring the allosteric inhibition of human kidney type glutaminase. Oncotarget. 2016;7(36):57943–57954.
   PubMedGoogle Scholar
• McDermott LA, Iyer P, Vernetti L, Rimer S, Sun J, Boby M, Yang T, Fioravanti M, O'Neill J, Wang L, et al. Design and evaluation of novel glutaminase inhibitors. Bioorg Med Chem. 2016;24(8):1819–1839.
   PubMed Web of Science ®Google Scholar
• Robinson MM, McBryant SJ, Tsukamoto T, Rojas C, Ferraris DV, Hamilton SK, Hansen JC, Curthoys NP. Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem J. 2007;406(3):407–414.
   PubMedGoogle Scholar
• Soth MJ, Le K, Di Francesco ME, Hamilton MM, Liu G, Burke JP, Carroll CL, Kovacs JJ, Bardenhagen JP, Bristow CA, et al. Discovery of IPN60090, a clinical stage selective Glutaminase-1 (GLS-1) inhibitor with excellent pharmacokinetic and physicochemical properties. J Med Chem. 2020;63(21):12957–12977.
   PubMed Web of Science ®Google Scholar
• Xu X, Wang J, Wang M, Yuan X, Li L, Zhang C, Huang H, Jing T, Wang C, Tong C, et al. Structure-enabled discovery of novel macrocyclic inhibitors targeting glutaminase 1 allosteric binding site. J Med Chem. 2021;64(8):4588–4611.
   PubMed Web of Science ®Google Scholar
• Lee EJ, Duggirala KB, Lee Y, Yun MR, Jang J, Cyriac R, Jung ME, Choi G, Chae CH, Cho BC, et al. Novel allosteric glutaminase 1 inhibitors with macrocyclic structure activity relationship analysis. Bioorg Med Chem Lett. 2022;75:128956.
   PubMed Web of Science ®Google Scholar
• Biancur DE, Paulo JA, Małachowska B, Del Rey MQ, Sousa CM, Wang X, Sohn ASW, Chu GC, Gygi SP, Harper JW, et al. Compensatory metabolic networks in pancreatic cancers upon perturbation of glutamine metabolism. Nat Commun. 2017;8(1):15965.
   PubMedGoogle Scholar
• Méndez-Lucas A, Lin W, Driscoll PC, Legrave N, Novellasdemunt L, Xie C, Charles M, Wilson Z, Jones NP, Rayport S, et al. Identifying strategies to target the metabolic flexibility of tumours. Nat Metab. 2020;2(4):335–350.
   PubMedGoogle Scholar
• Shen YA, Hong J, Asaka R, Asaka S, Hsu FC, Rahmanto YS, Jung JG, Chen YW, Yen TT, Tomaszewski A, et al. Inhibition of the MYC-regulated glutaminase metabolic axis is an effective synthetic lethal approach for treating chemoresistant ovarian cancers. Cancer Res. 2021;80(20):4514–4526.
   Web of Science ®Google Scholar
• Momcilovic M, Bailey ST, Lee JT, Fishbein MC, Magyar C, Braas D, Graeber T, Jackson NJ, Czernin J, Emberley E, et al. Targeted inhibition of EGFR and glutaminase induces metabolic crisis in EGFR mutant lung cancer. Cell Rep. 2017;18(3):601–610.
   PubMed Web of Science ®Google Scholar
• Elgogary A, Xu Q, Poore B, Alt J, Zimmermann SC, Zhao L, Fu J, Chen B, Xia S, Liu Y, et al. Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer. Proc Natl Acad Sci U S A. 2016;113(36):E5328–E5336.
   PubMed Web of Science ®Google Scholar
• Reckzeh ES, Karageorgis G, Schwalfenberg M, Ceballos J, Nowacki J, Stroet MCM, Binici A, Knauer L, Brand S, Choidas A, et al. Inhibition of glucose transporters and glutaminase synergistically impairs tumor cell growth. Cell Chem Biol. 2019;26(9):1214–1228.e25.
   PubMed Web of Science ®Google Scholar
• Momcilovic M, Bailey ST, Lee JT, Fishbein MC, Braas D, Go J, Graeber TG, Parlati F, Demo S, Li R, et al. The GSK3 signaling axis regulates adaptive glutamine metabolism in lung squamous cell carcinoma. Cancer Cell. 2018;33(5):905–921.e5.
   PubMed Web of Science ®Google Scholar
• Das DS, Ravillah D, Ray A, Song Y, Munshi NC, Richardson PG, Chauhan D, Anderson KC. Anti-myeloma activity of a novel glutaminase inhibitor CB-839. Blood. 2014;124(21):3439–3439.
   Google Scholar
• Meric-Bernstam F, Tannir NM, Mier JW, DeMichele A, Telli ML, Fan AC, Munster PN, Carvajal RD, Orford KW, Bennett MK, et al. Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC). JCO. 2016;34(15_suppl):4568–4568.
   Web of Science ®Google Scholar
• López de la Oliva AR, Campos-Sandoval JA, Gómez-García MC, Cardona C, Martín-Rufián M, Sialana FJ, Castilla L, Bae N, Lobo C, Peñalver A, et al. Nuclear translocation of glutaminase GLS2 in human cancer cells associates with proliferation arrest and differentiation. Sci Rep. 2020;10(1):2259.
   PubMed Web of Science ®Google Scholar
• Hu W, Zhang C, Wu R, Sun Y, Levine A, Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci U S A. 2010;107(16):7455–7460.
   PubMed Web of Science ®Google Scholar
• Dias MM, Adamoski D, dos Reis LM, Ascenção CFR, de Oliveira KRS, Mafra ACP, da Silva Bastos AC, Quintero M, de G. Cassago C, Ferreira IM, et al. GLS2 is protumorigenic in breast cancers. Oncogene. 2020;39(3):690–702.
   PubMed Web of Science ®Google Scholar
• Xiang L, Xie G, Liu C, Zhou J, Chen J, Yu S, Li J, Pang X, Shi H, Liang H. Knock-down of glutaminase 2 expression decreases glutathione, NADH, and sensitizes cervical cancer to ionizing radiation. Biochim Biophys Acta. 2013;1833(12):2996–3005.
   PubMed Web of Science ®Google Scholar
• Wang J-B, Erickson JW, Fuji R, Ramachandran S, Gao P, Dinavahi R, Wilson KF, Ambrosio ALB, Dias SMG, Dang CV, et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell. 2010;18(3):207–219.
   PubMed Web of Science ®Google Scholar
• Lukey MJ, Cluntun AA, Katt WP, Lin MJ, Druso JE, Ramachandran S, Erickson JW, Le HH, Wang Z-E, Blank B, et al. Liver-type Glutaminase GLS2 is a druggable metabolic node in luminal-subtype breast cancer. Cell Rep. 2019;29(1):76–88.e7.
   PubMed Web of Science ®Google Scholar
• Lee Y-Z, Yang C-W, Chang H-Y, Hsu H-Y, Chen I-S, Chang H-S, Lee C-H, Lee J, Ramesh Kumar C, Qiu Y-Q, et al. Discovery of selective inhibitors of Glutaminase-2, which inhibit mTORC1, activate autophagy and inhibit proliferation in cancer cells. Oncotarget. 2014;5(15):6087–6101.
   PubMedGoogle Scholar
• Stine ZE, Schug ZT, Salvino JM, Dang CV. Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discov. 2022;21(2):141–162.
   PubMed Web of Science ®Google Scholar
• Talantova M, Sanz-Blasco S, Zhang X, Xia P, Akhtar MW, Okamoto S, Dziewczapolski G, Nakamura T, Cao G, Pratt AE, et al. Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci U S A. 2013;110(27):E2518–E2527.
   PubMed Web of Science ®Google Scholar
• Deb S, Dutta A, Phukan BC, Manivasagam T, Justin Thenmozhi A, Bhattacharya P, Paul R, Borah A. Neuroprotective attributes of L-theanine, a bioactive amino acid of tea, and its potential role in Parkinson’s disease therapeutics. Neurochem Int. 2019;129:104478.
   PubMed Web of Science ®Google Scholar
• Bayraktar A, Li X, Kim W, Zhang C, Turkez H, Shoaie S, Mardinoglu A. Drug repositioning targeting glutaminase reveals drug candidates for the treatment of Alzheimer’s disease patients. J Transl Med. 2023;21(1):332.
   PubMed Web of Science ®Google Scholar
• Chassain C, Bielicki G, Donnat J, Renou J, Eschalier A, Durif F. Cerebral glutamate metabolism in Parkinson’s disease: an in vivo dynamic C NMS study in the rat. Exp Neurol. 2005;191(2):276–284.
   PubMed Web of Science ®Google Scholar
• Jin J, Byun J-K, Choi Y-K, Park K-G. Targeting glutamine metabolism as a therapeutic strategy for cancer. Exp Mol Med. 2023;55(4):706–715.
   PubMed Web of Science ®Google Scholar
• Ma G, Zhang Z, Li P, Zhang Z, Zeng M, Liang Z, Li D, Wang L, Chen Y, Liang Y, et al. Reprogramming of glutamine metabolism and its impact on immune response in the tumor microenvironment. Cell Commun Signal. 2022;20(1):114.
   PubMed Web of Science ®Google Scholar
• Kono M, Yoshida N, Maeda K, Suárez‐Fueyo A, Kyttaris VC, Tsokos GC. Glutaminase 1 inhibition reduces glycolysis and ameliorates lupus‐like disease in mrl/lpr mice and experimental autoimmune encephalomyelitis. Arthritis Rheumatol. 2019;71(11):1869–1878.
   PubMed Web of Science ®Google Scholar